ALTIMMUNE, INC.

ALT · NASDAQ

Pharmaceutical Preparation Manufacturing · US

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).

Market Data

Price $2.93 -0.06 (-2.01%)

Market Cap$575M

P/E Ratio—

EPS$—

52W High$6.44

52W Low$2.56

Beta0.13

Data from Finnhub · Updated Jul 15, 2026